Market Overview

BioCryst Prices 4M Share Offering at $4.40/Share


BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the
pricing of an underwritten public offering of 4,000,000 shares of its
common stock, offered at a price to the public of $4.40 per share. The
gross proceeds from this offering to BioCryst are expected to be $17.6
million, before deducting underwriting discounts and commissions and
other estimated offering expenses payable by BioCryst. BioCryst has
granted the underwriters a 30-day option to purchase up to an aggregate
of 600,000 shares of common stock to cover over-allotments, if any. The
offering is expected to close on or about August 6, 2013, subject to
customary closing conditions. BioCryst expects to use net proceeds of
this offering for general corporate purposes, including funding clinical
development of

See full press release

Posted-In: News Guidance Contracts Global


Related Articles (BCRX)

View Comments and Join the Discussion!

Sagent Pharmaceuticals Launches Docetaxel Injection Concentrate

Sanofi Announces FDA Panel Recommends Approval of Nasacort Spray